Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

BACKGROUND: Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson’s disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS Drugs
Hauptverfasser: Elmer, Lawrence W., Juncos, Jorge L., Singer, Carlos, Truong, Daniel D., Criswell, Susan R., Parashos, Sotirios, Felt, Larissa, Johnson, Reed, Patni, Rajiv
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2018
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934466/
https://ncbi.nlm.nih.gov/pubmed/29532440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-018-0498-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge